Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-8.49 Insider Own0.30% Shs Outstand392.44M Perf Week4.42%
Market Cap129.06B Forward P/E15.33 EPS next Y21.45 Insider Trans- Shs Float391.05M Perf Month8.37%
Income-2262.20M PEG- EPS next Q4.39 Inst Own90.80% Short Float1.24% Perf Quarter16.27%
Sales14.64B P/S8.81 EPS this Y-40.80% Inst Trans-0.01% Short Ratio2.28 Perf Half Y20.35%
Book/sh229.62 P/B1.43 EPS next Y19.99% ROA-3.20% Target Price348.32 Perf Year52.57%
Cash/sh5.43 P/C60.57 EPS next 5Y17.25% ROE-6.50% 52W Range201.91 - 340.34 Perf YTD27.76%
Dividend0.20 P/FCF66.15 EPS past 5Y-42.20% ROI-2.70% 52W High-3.37% Beta0.32
Dividend %0.06% Quick Ratio1.00 Sales past 5Y36.10% Gross Margin54.10% 52W Low62.88% ATR7.53
Employees21600 Current Ratio1.40 Sales Q/Q59.50% Oper. Margin-10.80% RSI (14)59.67 Volatility2.76% 1.88%
OptionableYes Debt/Eq0.67 EPS Q/Q-436.40% Profit Margin-14.80% Rel Volume1.31 Prev Close337.99
ShortableNo LT Debt/Eq0.64 EarningsAug 06 BMO Payout- Avg Volume2.13M Price328.87
Recom1.70 SMA204.16% SMA506.68% SMA20016.29% Volume2,790,738 Change-2.70%
Jul-28-15Reiterated Leerink Partners Outperform $354 → $388
Jul-28-15Reiterated Canaccord Genuity Buy $352 → $396
Jul-17-15Downgrade RBC Capital Mkts Top Pick → Outperform $361
Jul-30-15 05:02PM  Teva Pharmaceutical (TEVA) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
01:27PM  Buy Allergan as emerging aesthetics drug pure play
01:01PM  From Actavis to Allergan: One pharma companys wild dealmaking journey at Fortune
11:55AM  Ackman Wolf Pack' Sent Allergan to Foreigners, Ex-CEO Says
11:53AM  Former Allergan CEO is still going after Pershing at CNBC
11:14AM  Ackmans Wolf Pack Sent Allergan to Foreign Hands, Ex-CEO Says at Bloomberg
11:02AM  Senate Uses Valeant Pharma, Burger King, AB InBev To Expose Unequal Corporate Taxation In U.S. at Forbes
08:00AM  Allergan Confirms Generic Tyvaso┬« Patent Challenge PR Newswire
06:00AM  Warren Buffetts Family Secretly Funded a Birth Control Revolution at Bloomberg
Jul-29-15 09:00PM  Valeant Tells Congress a Very Different Tax Tale Than Investors
10:06AM  Mylan gets European clearance in proposed Perrigo takeover
09:12AM  5 Stocks With Notable Short-Selling Activity
09:06AM  Why Alcons Performance Was Weak in 2Q15
08:54AM  RBC Says Stay Away From Mylan, Perrigo; Go Long Teva, Allergan
08:22AM  Analysts' Actions -- Amazon, Caterpillar and Yelp
Jul-28-15 06:43PM  I'm investing here, avoiding this: Leon Cooperman at CNBC
06:13PM  Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
05:58PM  Teva Pharma to Acquire Allergan: Analysts Weigh In at Investopedia
04:28PM  Leon Cooperman: Allergan trying to move up
03:22PM  Allergan's Healthy Price May Come With Side Effects at The Wall Street Journal
01:10PM  There's 'Life After Teva' For Mylan, Says Leerink at
12:34PM  BMO Ups Teva To Buy; Allergan Deal 'Solidifies Leadership' In Generics at
10:50AM  Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
10:43AM  Allergan (AGN) Stock Gaining on Canaccord Price Target Increase at TheStreet
10:02AM  Wait, Will Allergan Really Buy Biogen or Amgen? at
09:44AM  Faber Report: Mylan continues fight for Perrigo
09:18AM  Allergan (AGN) in Focus: Stock Jumps 6.1% - Tale of the Tape
08:01AM  The real reasons for the pharma merger boom at Fortune
07:44AM  Dissecting big pharma's numbers: Pro
06:00AM  Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Commentary
12:31AM  PRESS DIGEST- New York Times business news - July 28 Reuters
12:17AM  Tevas Allergan Deal Looks a Healthier Mouthful at The Wall Street Journal
12:17AM  Allergans Healthy Price May Come With Side Effects at The Wall Street Journal
Jul-27-15 11:12PM  Allergan sells generic drug unit to Israel's Teva for $40.5 billion at Los Angeles Times +6.09%
06:28PM  Baidu U.S. shares fall on earnings miss, revenue forecast at MarketWatch
05:47PM  [video]Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid at TheStreet
05:45PM  Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergans Pending Acquisition of KYTHERA GlobeNewswire
05:36PM  Does This Statistic Point To Market Low Or More Pain? at Investor's Business Daily
05:29PM  Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid
05:23PM  Next biotech deal brewing?
05:22PM  Teva buys Allergan: 3 reasons why its a blockbuster deal at Fortune
05:22PM  Teva Tags Allergan's Generics: $40.5 Bil
04:45PM  Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA PR Newswire
04:09PM  Teva Snaps Up Allergan's Generics Arm, Dumping Mylan
04:05PM  Allergan signals appetite for new mega deal after $41bn disposal at Financial Times
04:05PM  [video]Stocks Down in the Dumps as Chinese Market Slumps at TheStreet
03:17PM  Teva Can Reach $100 on Allergan Unit Acquisition at
03:14PM  Allergan to own 10% stake in Teva
01:56PM  3 Health Care Stocks to Trade for Gains at TheStreet
01:33PM  Pharma M&A: portfolio theory at Financial Times
12:54PM  The $100 Billion Deal Is Still Out There for Pharma: Real M&A at Bloomberg
12:34PM  Teva to Buy Allergan Generics for $40.5 Billion at The Wall Street Journal
12:15PM  Biogen Seen as Takeover Target After Fridays Stock Plummet at Bloomberg
12:15PM  Top holdings in health care: Pro
12:08PM  Teva Buys Allergan Unit: How Mylan, Other Biotech Stocks Are Reacting
12:01PM  Allergan May Turn Sights to Amgen or AbbVie With Cash From Teva at Bloomberg
12:00PM  U.S. Stocks Follow Global Markets Lower
11:53AM  Teva Pharmaceutical to Buy Allergan's Generics Unit in $40.5 Billion Deal - Stocks in the News
11:43AM  Allergan CEO, fresh off one deal, sets sights on others
11:39AM  Teva to Buy Allergan's Generic Drug Unit
11:30AM  Europe stocks close 2% down after China rout at CNBC
11:30AM  Teva deal pushes Allergan up, Mylan down; GrubHub downgraded
11:11AM  Teva to acquire Allergan for $40B
10:51AM  Teva Drops Mylan Chase To Buy Allergan Generics Unit at Investor's Business Daily
10:48AM  Teva Pharmaceutical Industries Ltd (TEVA) Ascends On Allergan PLC (AGN) Generics Purchase, Mylan NV (MYL) Withdrawal at Insider Monkey
10:37AM  Teva CEO Sees More Deals After $40.5 Billion Allergan Purchase at Bloomberg
10:31AM  Teva Pharmaceuticals Stands To Lose Around $300 Million On Mylan Trade at Forbes
10:22AM  The Last-Minute Phone Call That Spurred Teva Deal With Allergan at Bloomberg
10:10AM  Allergan (AGN) Stock Rises After $40.5 Billion Generic Drug Business Sale at TheStreet
10:09AM  Mylan share price plunges after Teva abandons bid at Financial Times
10:08AM  Teva to acquire Allergan generics unit
10:01AM  Allergan: Pharma's Biggest Dealmaker Is On The Hunt Again at Forbes
09:56AM  Kythera Wins Canadian Approval for Double-Chin Injection at The Wall Street Journal
09:36AM  Stocks Drop as Chinese Markets Fall at Fastest Pace Since 2007 at TheStreet
09:13AM  Morning Movers: Teva Gains on Allergan Generics Bid; Chesapeake Energy Gains on Upgrade at
09:10AM  Teva Confirms Allergan Generics Buy, Drops Mylan Bid at Investor's Business Daily
09:05AM  July 27 Premarket Briefing: 10 Things You Should Know
09:05AM  Full Interview: Allergan's CEO On Selling His Generics Business And What He'll Buy Next at Forbes
09:02AM  Teva-Allergan deal; Burger King beat; Facebook web move
08:59AM  U.S. Stocks On Track For Weak Open As Chinese Stocks Sink at Investor's Business Daily
08:55AM  Teva drops bid for Mylan, buys Allergan's generic drug unit at
08:53AM  Cramer's stocks to watch: Allergan's big win
08:24AM  Quarterly Capitalism and Secret Drachmas
08:14AM  Israel's Teva buys Allergan generic drug company for $40.5B
08:13AM  Investors eye China, durable goods; Teva deal; Hollywood's new backer
07:57AM  Teva to buy Allergan generics for $40.5 billion at MarketWatch
07:48AM  Early movers: AGN, MYL, MHFI, UBS, FCAU & more at CNBC
07:38AM  Teva to buy Allergan's generics business for $40.5B at CNBC
07:23AM  What You Need to Know: China, UBS, TEVA
07:16AM  Israeli drug firm Teva buys Allergans generics business for $40 billion at Fortune
06:35AM  Teva made smart decision to move to us: Allergan CEO
06:32AM  Allergan CEO: Here's why we sold to Teva...
06:06AM  Allergan sells generic drugs unit to Teva for $40bn at Financial Times
06:04AM  Teva to acquire Allergan generics for $40.5B
05:46AM  Teva to buy Allergan generic drug business for $40.5 bln
05:31AM  Teva Purchasing Allergan's Generics Unit in $40.5B Deal
05:00AM  Teva to Buy Allergan's Generics Business for $40.5B
04:44AM  Teva Will Buy Allergan Generics for $40.5 Billion at 24/7 Wall St.
04:41AM  Teva Snaps Up Allergans Generics Arm, Dumping Mylan at Bloomberg
04:37AM  Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion PR Newswire
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician's offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PYOTT DAVID E IChairman of the Board and CEOFeb 20Option Exercise0.001,3790166,379Feb 24 09:52 PM
Gangolli Julian SCVP & Pres, North AmericaFeb 20Option Exercise0.0051402,418Feb 24 09:44 PM